文献速递肿瘤 PET/CT核素与放射性配体治疗

根治性前列腺切除术后生化复发患者游离与总PSA比值与18F-DCFPyL前列腺特异性膜抗原PET/CT表现的相关性:一项前瞻性单中心研究

Association of Free-to-Total PSA Ratio and 18F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study.
PubMed 文献 · J Nucl Med · 2024-11-01

这项前瞻性单中心研究纳入137例根治性前列腺切除术后生化复发且总PSA小于1 ng/mL、转诊行18F-DCFPyL PSMA PET/CT的患者,于PET/CT当日采血计算游离与总PSA比值(FPSAR)。FPSAR≥0.10是18F-DCFPyL PSMA PET/CT阳性的独立预测因子,比值比为6.99(95%CI,2.96-16.51;P<0.001)。

要点

  • 137例术后生化复发患者中,86例(62.8%)FPSAR<0.10,51例(37.2%)FPSAR≥0.10。
  • FPSAR≥0.10是18F-DCFPyL PSMA PET/CT阳性的独立预测因子,OR为6.99(95%CI,2.96-16.51;P<0.001)。
  • 作者认为该发现可能提供一种低成本方法,在PSMA PET/CT可及性不足的地区用于分诊安排检查。

核心结论

  • 根治性前列腺切除术后生化复发患者中,FPSAR≥0.10与18F-DCFPyL PSMA PET/CT阳性几率升高独立相关。
  • 作者认为这些发现可能提供一种低成本方法,在18F-DCFPyL PSMA PET/CT可及性不足的地区用于分诊安排检查。

研究设计与样本

  • 前瞻性单中心研究,纳入137例根治性前列腺切除术后生化复发(包括辅助或挽救放疗)且总PSA小于1 ng/mL、转诊行18F-DCFPyL PSMA PET/CT的患者。
  • 于18F-DCFPyL PSMA PET/CT当日采集血样计算FPSAR,并将FPSAR分为小于0.10或0.10及以上。
  • 18F-DCFPyL PSMA PET/CT阳性定义为PROMISE分类病灶评分2或3,不论示踪剂摄取增高部位(如前列腺、盆腔淋巴结、骨或内脏)。

主要发现

  • 共分析137例根治性前列腺切除术后生化复发患者的血样以计算FPSAR。
  • 18F-DCFPyL PSMA PET/CT时的中位年龄为68.6岁(四分位距,63.0-72.4岁),中位PSA为0.3 ng/mL(四分位距,0.3-0.6 ng/mL)。
  • 86例(62.8%)FPSAR小于0.10,51例(37.2%)FPSAR为0.10及以上。
  • FPSAR≥0.10被确定为18F-DCFPyL PSMA PET/CT阳性的独立预测因子,比值比为6.99(95%CI,2.96-16.51;P<0.001)。

关键数值与推荐

  • FPSAR分组阈值:小于0.10或0.10及以上。
  • PET/CT阳性判定:PROMISE分类病灶评分2或3。
  • FPSAR≥0.10预测PET/CT阳性的OR为6.99(95%CI,2.96-16.51;P<0.001)。

临床怎么用

  • 作者认为FPSAR≥0.10与18F-DCFPyL PSMA PET/CT阳性几率升高独立相关,可能提供一种低成本方法,在PSMA PET/CT可及性不足的地区用于分诊安排检查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In Canada and across the globe, access to PSMA PET/CT is limited and expensive. For patients with biochemical recurrence (BCR) after treatment for prostate cancer, novel strategies are needed to better stratify patients who may or may not benefit from a PSMA PET scan. The role of the free-to-total prostate-specific antigen (PSA) ratio (FPSAR) in posttreatment prostate cancer, specifically in the PSMA PET/CT era, remains unknown. Our aim in this study was to determine the association of FPSAR in patients referred for 18F-DCFPyL PSMA PET/CT in the BCR setting and assess the correlation between FPSAR and 18F-DCFPyL PSMA PET/CT positivity (local recurrence or distant metastases). Methods: This prospective study included 137 patients who were referred for 18F-DCFPyL PSMA PET/CT and had BCR with a total PSA of less than 1 ng/mL after radical prostatectomy (RP) (including adjuvant or salvage radiotherapy). Blood samples were collected on the day of 18F-DCFPyL PSMA PET/CT. FPSAR was categorized as less than 0.10 or as 0.10 or more. A positive 18F-DCFPyL PSMA PET/CT scan was defined by a PROMISE classification lesion score of 2 or 3, irrespective of the site of increased tracer uptake (e.g., prostate, pelvic nodes, bone, or viscera). Results: Overall, 137 blood samples of patients with BCR after RP were analyzed to calculate FPSAR. The median age at 18F-DCFPyL PSMA PET/CT was 68.6 y (interquartile range, 63.0-72.4 y), and the median PSA at 18F-DCFPyL PSMA PET/CT was 0.3 ng/mL (interquartile range, 0.3-0.6 ng/mL). Eighty-six patients (62.8%) had an FPSAR of less than 0.10, whereas 51 patients (37.2%) had an FPSAR of 0.10 or more. An FPSAR of 0.10 or more was identified as an independent predictor of a positive 18F-DCFPyL PSMA PET/CT scan, with an odds ratio of 6.99 (95% CI, 2.96-16.51; P < 0.001). Conclusion: An FPSAR of 0.10 or more after RP independently correlated with increased odds of a positive 18F-DCFPyL PSMA PET/CT scan among BCR post-RP patients. These findings may offer an inexpensive method by which to triage access to 18F-DCFPyL PSMA PET/CT in jurisdictions where availability is not replete.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bernardino RM, Lajkosz K, Yin LB, et al. Association of Free-to-Total PSA Ratio and 18F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study. J Nucl Med. 2024. PMID: 39327019. doi:10.2967/jnumed.124.267877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。